Natera Inc. Common Stock vs TJX Companies Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while TJX Companies Inc trades at $143.3 (market cap $155.64B). The key difference: TJX Companies Inc is far larger — about 2.7× Natera Inc. Common Stock's market cap, and TJX Companies Inc pays a 1.36% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and TJX Companies Inc for 97 Days on average.
| NTRA | TJX | |
|---|---|---|
Market Cap | $57.03B | $155.64B |
Volume | 1,131,157 | 7,499,607 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $168.41 |
52-Week Low | $179.42 | $122.84 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $56.18B | $163.95B |
Dividend Yield | — | 1.36% |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TJX trades at $142.80, up 0.62% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $56.36B in 2025, with net income of $4.86B and a high ROE of 62.17%. The stock is near its pivot point of $141, with resistance at $143 and support at $139. Analysts are overwhelmingly positive, with an 84.9% buy rating and a consensus price target of $174.15.
Outlook remains positive due to consistent earnings outperformance and projected revenue growth to $62.4B in 2026. Risks include high valuation multiples (P/E 26.2) and competitive pressures in off-price retail. Upside potential is supported by Wall Street optimism and strong cash flow trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →